Autolus Therapeutics plc filed a Form 8-K with the U.S. Securities and Exchange Commission on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026, and furnishing an updated corporate presentation used in a same-day conference call.

Key Highlights

  • Filing date: August 11, 2026, covering the quarter ended June 30, 2026.
  • Results announcement: Autolus Therapeutics disclosed its financial results for Q2 2026 via a press release furnished as Exhibit 99.1.
  • Corporate presentation: An updated corporate presentation, Exhibit 99.2, was furnished in connection with a conference call held on August 11, 2026.
  • Furnished, not filed: The information in Items 2.02 and 7.01, including both exhibits, is furnished and "shall not be deemed filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
  • Signed by CEO: The report was signed by Christian Itin, Ph.D., Chief Executive Officer, on August 11, 2026.

Autolus Therapeutics Furnishes Q2 2026 Press Release and Corporate Presentation

Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company incorporated in England and Wales and headquartered in London, filed a Current Report on Form 8-K on August 11, 2026. According to the filing, the company announced its financial results for the quarter ended June 30, 2026, and provided a corporate update through a press release dated August 11, 2026, furnished as Exhibit 99.1.

The filing also discloses, under Item 7.01 (Regulation FD Disclosure), that the company utilized an updated corporate presentation in connection with a conference call on August 11, 2026, to discuss its quarterly results. That presentation is furnished as Exhibit 99.2. The filing notes that the American Depositary Shares (ADS) listed on The Nasdaq Global Select Market each represent one ordinary share with a nominal value of $0.000042 per share.

The filing explicitly states that the information in Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, is being furnished and "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." As a result, the exhibits are not incorporated by reference into any of the company's other filings under the Securities Act or the Exchange Act unless expressly specified. The report was signed on behalf of the registrant by Chief Executive Officer Christian Itin, Ph.D.

What Was Disclosed

Autolus Therapeutics plc furnished a Q2 2026 earnings press release and an updated corporate presentation on August 11, 2026, via a Form 8-K. Both exhibits are furnished, not filed, and are therefore not subject to Section 18 liabilities of the Exchange Act.